The outlook in<unk>  is variable, with about 30% of patients progressing to refractory AML. The median survival time varies from years to months, depending on type. Stem-cell transplantation offers possible cure, with survival rates of 50% at 3 years, although older patients do poorly. Indicators of a good prognosis: Younger age; normal or moderately reduced neutrophil or platelet counts; low blast counts in the bone marrow (3 chromosomal aberrations); chromosome 7 anomalies The IPSS is the most commonly used tool in<unk>  to predict long-term outcome. Cytogenetic abnormalities can be detected by conventional cytogenetics, a FISH panel for<unk> , or virtual karyotype. Genetic markers Although not yet formally incorporated in the generally accepted classification systems, molecular profiling of<unk>  genomes has increased the understanding of prognostic molecular factors for this disease. For example, in low-risk<unk> , IDH1 and IDH2 mutations are associated with significantly worsened survival.
Myelodysplastic syndrome
Primary myelofibrosis
Acute myeloid leukemia
Myeloid leukemia
Autoimmune neutropenia
Mixed-phenotype acute leukemia
Childhood leukemia
B-cell leukemia